Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
Trial details
- Registry ID
- NCT04475432
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
Also recorded as Lotilaner ophthalmic solution, 0.25%
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety and Efficacy of TP-03 for the Treatment of Demodex BlepharitisNCT04475432 | TARS | Phase 2, Phase 3 | Completed | 2021-05-04Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |